We are entering a new chapter in obesity medicine — and the stakes have never been higher.
Not long ago, the conversation around GLP-1 receptor agonists was dominated by two frustrating realities: inconsistent insurance coverage and the rapid proliferation of low-cost compounded alternatives. For many patients, treatment decisions were shaped less by clinical appropriateness and more by a simple, urgent calculus of availability, affordability, and desperation.
Scarcity. Coverage exclusions. Compounding workarounds. Treatment shaped by what patients could access, not what they clinically needed.
Price-accessible incretins. Broader formulations. The molecule problem is being solved. The expertise problem is just beginning.
Access alone does not guarantee outcomes. In Era 2, expertise will define them.
Era 1: Scarcity, Friction, and Workarounds
Early adoption of GLP-1 therapies for obesity collided with a set of structural barriers that had little to do with medicine and everything to do with the systems surrounding it. Coverage exclusions denied therapy to qualifying patients. Out-of-pocket costs forced impossible trade-offs. Supply constraints interrupted treatment mid-course. And in some markets, widespread reliance on compounded formulations filled the void — inconsistently and imperfectly.
While pivotal trials demonstrated unprecedented efficacy, real-world treatment often looked very different. Patients cycled on and off therapy as their access fluctuated, doses were inconsistently escalated, and clinical monitoring varied dramatically from one practice to the next.
The trial data set a remarkable bar. STEP-1 (semaglutide) reported mean weight loss of approximately 15% under the treatment-policy estimand — reaching nearly 17% on the trial-product estimand — under highly controlled conditions with expert oversight and structured follow-up. SURMOUNT-1 (tirzepatide) demonstrated mean weight loss ranging from approximately 15% to over 20% depending on dose, with the highest dose cohort exceeding 22% under the efficacy estimand.1,2
Yet observational data soon told a more sobering story.
The Persistence Problem
Across multiple real-world analyses, persistence with GLP-1 therapies has been strikingly — and consistently — low. High dropout rates within the first year. Significant early discontinuation driven by cost, access disruptions, and tolerability challenges. Meaningfully attenuated weight loss among patients who did not remain on therapy.
Large-scale real-world datasets have confirmed that a substantial proportion of patients discontinue GLP-1 therapy within 12 months — a finding replicated across payer databases and health system datasets.5,6
This is not a medication failure. It is a delivery-of-care failure.
Era 2: Price-Accessible Incretins Change the Equation
As newer incretin therapies reach the market — including dual GIP/GLP-1 agonists such as tirzepatide and emerging triple agonists such as retatrutide — alongside oral formulations, multidose delivery systems, and evolving pricing strategies, a major barrier is beginning to soften.
The molecule problem is being solved.
But a new differentiator is taking its place: who actually knows how to prescribe, titrate, monitor, and support these therapies effectively?
GLP-1 and dual/triple incretin therapies are not simple prescriptions. They require a clinical infrastructure that most practices have not yet built:
- Careful, individualized dose escalation
- Proactive side-effect anticipation and management
- Nutritional guidance calibrated to medication-induced satiety changes
- Behavioral support addressing the psychological dimensions of weight change
- Body composition monitoring to protect lean mass
- Clear decision pathways for adjunctive interventions when pharmacotherapy alone is insufficient
Without this infrastructure, predictable problems arise — quickly. Early discontinuation, poor tolerability, suboptimal dosing, unrealistic expectations, and blunted outcomes are not inevitable. They are the predictable consequences of prescribing powerful tools without the systems to support them.
Why Expertise Matters More Than Ever
Clinical trials succeed because they are run by experts within systems purpose-built to protect persistence and optimize tolerability. Patients are seen frequently. Side effects are managed proactively. Doses escalate on schedule. Nutritional and behavioral support is integrated from the start. Dropouts are minimized not by accident, but by design.
In routine care, outcomes depend entirely on whether similar rigor exists. Expert-driven programs are distinguished by their infrastructure, not merely their prescribers:
- Proactive side-effect mitigation built into the first appointment
- Structured, protocol-driven titration schedules
- Registered dietitian integration from day one
- Behavioral health intervention, on-site or by referral
- Frequent follow-up — especially in the first 12 weeks
- Early rescue strategies when tolerability challenges emerge
These are not program luxuries. They are outcome-determinants. Practices that build this infrastructure will separate themselves from those that simply prescribe.
Medications Alone Are Not the Full Story
Obesity is a chronic, heterogeneous disease. No single therapy works optimally for every patient, and the highest-performing programs have long recognized that pharmacotherapy is one tool in a broader toolkit — not the destination.
High-performing obesity medicine programs increasingly integrate pharmacotherapy with endoscopic interventions, bariatric surgery, medical nutrition therapy, and behavioral care. When these modalities are appropriately sequenced and individualized, the combination produces outcomes that medication alone cannot reliably achieve.4
Weight maintenance data from the STEP 4 trial underscores the chronic nature of this condition: discontinuation of semaglutide after initial weight loss results in significant regain, reinforcing that these are chronic therapies that require chronic support structures.3
The Coming Divide
As incretins become more affordable and widely available, the market will not simply grow — it will differentiate. A widening performance gap is likely to emerge between two distinct models of care:
| Prescription-Only Model | Expertise-Driven Care |
|---|---|
| High early discontinuation | Structured persistence protocols |
| Tolerability-driven dropout | Proactive side-effect management |
| Variable dosing fidelity | Protocol-driven titration |
| Limited nutritional support | Dietitian-integrated care from day one |
| Blunted, inconsistent outcomes | Outcomes approaching trial-level efficacy |
The difference will manifest in persistence rates, safety profiles, patient satisfaction, durability of weight loss, and downstream metabolic outcomes. Patients who receive only the prescription will not realize the same benefit as those who receive the full program.
The Central Lesson of Era 2
The promise of this moment in obesity medicine is real. Incretins are increasingly accessible, more potent agents are arriving, and the disease is finally being treated with the pharmacologic seriousness it deserves.
But the lesson of Era 1 — written in the data of millions of patients who discontinued therapy before seeing its benefit — is clear:
It is not enough to prescribe powerful medications. You must know how to support the patient taking them.
The future of obesity care will not be defined solely by molecules. It will be defined by models of care capable of translating pharmacologic potential into real-world results — consistently, safely, and at scale.
The practices and programs building that infrastructure today are not simply ahead of the curve. They are defining what excellence in obesity medicine looks like for the next decade.